SUMMARY The incidence ofmucocutaneous herpes simplex virus infection confirmed by culture and occurring during febrile neutropenic episodes was determined in 43 patients with haematological malignancy. The outcome of72 episodes ofneutropenic fever was determined and correlated with the presence or absence of herpes simplex virus (HSV) infection. Twenty four patients had mucocutaneous HSV infection during at least one episode. In 24 episodes in which HSV was isolated only 12-5% of fevers responded to antibiotics and 75% of fevers were otherwise unexplained. Conversely, in 48 episodes of neutropenic fever in which HSV was not isolated 67% of fevers responded to antibiotics and only 8-3% were unexplained. The difference in incidence ofantibiotic resistant fever in the two groups was significant. There was, therefore, a strong association between mucocutaneous HSV infection and antibiotic resistant fever in immunosuppressed neutropenic patients. As most HSV infections are the result of virus reactivation, establishing the HSV serological state of patients would identify those at risk of infection and hence those in whom the prophylactic use of acyclovir would be indicated.
12-5% of fevers responded to antibiotics and 75% of fevers were otherwise unexplained. Conversely, in 48 episodes of neutropenic fever in which HSV was not isolated 67% of fevers responded to antibiotics and only 8-3% were unexplained. The difference in incidence ofantibiotic resistant fever in the two groups was significant. There was, therefore, a strong association between mucocutaneous HSV infection and antibiotic resistant fever in immunosuppressed neutropenic patients. As most HSV infections are the result of virus reactivation, establishing the HSV serological state of patients would identify those at risk of infection and hence those in whom the prophylactic use of acyclovir would be indicated.
Early treatment with broad spectrum bactericidal antibiotics reduces the morbidity and mortality from bacterial infection in neutropenic patients.' A significant proportion of febrile episodes which occur in neutropenic patients, however, fail to respond to broad spectrum antibiotics.' In these cases antibiotic resistant bacteria and invasive fungal and viral infections are sometimes identified.4 Reactivation of herpes simplex virus (HSV) is increasingly recognised in patients with haematological malignancy,56 and mucocutaneous infection is a major cause of morbidity in patients after bone marrow transplantation.78
An association between HSV infection and prolonged fever in recipients of allogeneic bone marrow transplants has been suggested,8 but HSV infection as a cause of persistent fever in neutropenic patients has not been confirmed. We therefore set out to determine the incidence of HSV infection in patients with haematological malignancy who were receiving intensive chemotherapy and to correlate this with the outcome of episodes of neutropenic fever.
Accepted for publication 13 July 1989 Patients and methods The records of febrile neutropenic patients in whom throat swabs for virus culture had been taken at the onset of fever were examined for details of infection, fever, bacterial isolates and response to antibiotics. Cultures from 13 swabs were discarded because of contamination with either bacteria or fungi. Of the remaining 148 swabs, HSV was cultured from 52 (32% of all swabs). Positive HSV cultures were obtained during 24 episodes ofneutropenic fever (mean number of positive swabs for each HSV infection = 2 2). In all cases patients were also lymphopenic ( < 1.0 x 109/1).
There was no correlation, however, between the incidence of HSV infection and the absolute lymphocyte count. Furthermore, there was no difference in lymphocyte counts at the time of infection in those patients with HSV (0O4 x 109/l) and those without HSV infection (0.5 x 109/1) (p = NS by Mann- Myeloid malignancies: Acute myeloblastic leukaemia 14 6 Chronic myeloid leukaemia 2 0
Aplastic anaemia 1 1
Lymphoid malignancies: Acute lymphoblastic leukaemia 4 3 High grade non-Hodgkin's lymphoma Baglin, Gray, Marcus, Wreghitt Whitney test). All HSV strains were serotyped as HSV type 1.
The same 43 patients had a further 152 surveillance throat swabs cultured for HSV when not febrile. Only 15 swabs from six patients grew HSV. None of the patients was febrile or neutropenic at the time swabs were taken, all but one were lymphopenic (< 1-0 x 109/1). These episodes were not associated with recent chemotherapy, five occurring in patients with active lymphoma and one following anti-lymphocyte globulin treatment for aplastic anaemia.
RESPONSE OF NEUTROPENIC FEVER TO ANTIBACTERIAL TREATMENT AND RELATION TO HSV INFECTION
Seventy two episodes of neutropenic fever were recorded. HSV was isolated at the time of fever in 24 episodes (33%) and was not cultured in 48 (67%). One patient in each group died, giving an overall mortality of 3%.
Only three (12-5%) of the 24 febrile neutropenic episodes in which HSV was cultured responded to antibacterial treatment. 
Discussion
Bacterial infection in neutropenic patients may be rapidly fatal, and as the results of bacterial cultures and hence antibiotic sensitivities are not immediately available patients are treated empirically with parenteral broad spectrum antibiotics. This approach has greatly reduced the mortality associated with episodes of neutropenic fever."~' The mortality during neutropenic fever in our study was 3% and the incidence of documented bacteraemia was 24%, both of which are comparable with the data of previous studies. ' Herpes virus infections are common in immunosuppressed patients.'0 The rate of HSV reactivation in patients with high grade lymphoproliferative malignancy has been reported to be as high as 60%," while a prospective point prevalence study in 29 patients with acute myeloblastic leukaemia showed a 34-5% HSV reactivation rate, with 40% of patients shedding HSV on at least one occasion.6 In our study 52% ofpatients with haematological malignancy had at least one documented episode of HSV infection during episodes of neutropenic fever.
Our data suggest that in patients at risk of reactivation of HSV, infection is associated with lymphopenia rather than neutropenia. This observation is in keeping with known mechanisms of T cell mediated defence against HSV.9 Among the lymphoid malignancies there were only two T cell high grade lymphomas and two cases of T cell acute lymphoblastic leukaemia. Most HSV infections, therefore, occurred in patients with B cell lymphomas. We suggest that this is because active HSV infection is associated with the severe lymphopenia associated with intensive chemotherapy rather than impairment of lymphocyte function associated with disease. As all the patients in this study were lymphopenic at times of neutropenia, neutropenic patients seem to be at risk of HSV infection by virtue of associated lymphopenia.
Notably, fever was only associated with HSV infection in our patients when they were lymphopenic and neutropenic following intensive cytotoxic chemotherapy. At this time the integrity of mucous membranes is also compromised and this may allow a portal of entry for organisms, particularly Gram positive bacteria.' 2 13 The high incidence of antibiotic resistant fever in neutropenic patients with HSV infection (87 5%), compared with those without (33%, p < 0-001) indicates the importance ofrecognising HSV infection as a contributory factor in persistent fever in neutropenic patients. Symptoms or signs suggestive of HSV infection, such as mouth ulceration, gingivitis, sore throat and oesophagitis were not documented in 70% of cases confirmed by culture. Undue reliance should not be placed, therefore, on the clinical findings alone.
Although the incidence of disseminated HSV infection is low, the prophylactic administration of acyclovir to HSV antibody positive patients during neutropenia might reduce not only morbidity, related to mucosal ulceration, but also the incidence of antibiotic resistant fever. This study did not prospectively evaluuate the response of fever to the therapeutic administration of acyclovir. In several prospective controlled studies, however, acyclovir has been shown to be effective in preventing HSV infection in patients with haematological malignancy. The pharmacokinetics of absorption of orally administered acyclovir do not seem to be significantly affected by gut toxicity,'4 and both oral"1" and intravenous8 15 prophylaxis with acyclovir are effective. Furthermore, significant resistance to acyclovir has not been found in our patients, despite altered susceptibility to acyclovir during treatment of established HSV infection, and oral therapy should be adequate in most if not all patients. '6 In conclusion, mucocutaneous HSV infection in immunosuppressed neutropenic patients is associated with antibiotic resistant fever. There is therefore a rational basis for the inclusion of acyclovir in the management of fever in these patients and its use may reduce that of intravenous amphotericin B and second line antibiotics. Because HSV infection is predominantly the result of virus reactivation, establishing the HSV seropositive state of patients would identify those at risk of infection and hence those in whom prophylaxis with acyclovir would be indicated.
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